This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fu, C.
Right arrow Articles by Wang, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fu, C.
Right arrow Articles by Wang, M.

 Previous Article  |  Next Article 

Clinical and Vaccine Immunology, September 2008, p. 1425-1428, Vol. 15, No. 9
1071-412X/08/$08.00+0     doi:10.1128/CVI.00122-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Matched Case-Control Study of Effectiveness of Live, Attenuated S79 Mumps Virus Vaccine against Clinical Mumps{triangledown}

Chuanxi Fu,* Jianhua Liang, and Ming Wang

Guangzhou Center for Disease Control and Prevention, Guangzhou, China

Received 5 April 2008/ Returned for modification 24 June 2008/ Accepted 21 July 2008

Mumps virus infection is a potentially serious viral infection of childhood and early adulthood. In China, live, attenuated S79 mumps virus vaccine has been licensed for pediatric use since 1990. There has been no assessment of its efficacy. Thus, the objective of this study was to determine the effectiveness of live, attenuated S79 mumps virus vaccine against clinical mumps. Cases were selected from the China Information System for Disease Control and Prevention during September 2004 to March 2005. Each case was matched to a control by gender, age, and area of residency. In all, 469 cases and 469 controls were enrolled in the study. Vaccination information was obtained from the Children's EPI Administrative Computerized System. Vaccine effectiveness (VE) was calculated for one or two doses of S79 vaccine, with 95% confidence intervals (CI). VE of mumps virus vaccine for one dose versus none was protection of 86.0% (95% CI, 77.2% to 91.5%) of recipients, and VE was much higher in the first 4 years than in the 5 to 12 years after vaccination. The S79 vaccine can effectively prevent clinical mumps, and a second dose of mumps virus vaccine is necessary for the protection of children in China.

* Corresponding author. Mailing address: Department of Expanded Programmed Immunization, Guangzhou Center for Disease Control and Prevention, Guangzhou, China. Phone: 0086 20 83838507. Fax: 0086 20 83709689. E-mail: fuchuanxi{at}gmail.com

{triangledown} Published ahead of print on 30 July 2008.

Clinical and Vaccine Immunology, September 2008, p. 1425-1428, Vol. 15, No. 9
1071-412X/08/$08.00+0     doi:10.1128/CVI.00122-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»